Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425482 | 0.97 | HPGD (0.58) | HPGDTSHRALDH1A1HRH3FKBP1A | |
| SCHEMBL8896530 | 0.86 | ALDH1A1 (0.58) | ALDH1A1KCNJ1LMNASMN1; SMN2 | |
| SCHEMBL8898022 | 0.86 | L3MBTL1 (0.64) | HPGDALDH1A1HRH3KCNJ1KCNH2 | |
| SCHEMBL8897735 | 0.84 | SMN1; SMN2 (0.57) | HPGDTSHRALDH1A1HRH3LMNA | |
| SCHEMBL4428749 | 0.78 | ALDH1A1 (0.60) | HPGDTSHRALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL4185130 | 0.77 | HTT (0.46) | ALDH1A1HRH3KCNJ1KCNH2LMNA | |
| SCHEMBL5650248 | 0.77 | HTT (0.46) | ALDH1A1HRH3KCNJ1KCNH2LMNA | |
| SCHEMBL14405008 | 0.77 | HTT (0.46) | ALDH1A1HRH3KCNJ1KCNH2LMNA | |
| SCHEMBL17676780 | 0.77 | ALDH1A1 (0.46) | ALDH1A1HRH3KCNJ1KCNH2LMNA | |
| SCHEMBL21681941 | 0.76 | ALDH1A1 (0.74) | ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | HPGD 355/4885TSHR 562/4885ALDH1A1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.